Speaker
Tom Dayspring
Appearances over time
1 episodes
Episodes
1
Podcasts
Quotes & moments
The brain contains roughly 20–25 grams of cholesterol — approximately 20 times more than the liver — because it stores cholesterol long-term rather than cycling it.
Cholesterol in the brain has a half-life of approximately 5 years, compared to just a few days in peripheral tissues, reflecting the brain's extreme conservation of its cholesterol stores.
Around age 10, when the brain reaches adult size, neurons cease synthesizing cholesterol themselves and rely entirely on astrocytes to supply it, freeing ATP for neural firing.
Synthesizing a single cholesterol molecule requires more than 30 molecules of ATP across 37 enzymatic steps, which is why neurons delegate cholesterol production to astrocytes once the brain is fully grown.
HDL particles (ApoA family) account for roughly 90% of all lipoproteins in the bloodstream by number, yet carry far less total cholesterol than the smaller but larger ApoB family.
Plasma desmosterol correlates highly with cerebrospinal fluid desmosterol and brain tissue cholesterol synthesis, making it a measurable blood biomarker of brain cholesterol production; low levels are associated with higher rates of cognitive impairment.
Elevated plasma 24S-hydroxycholesterol signals that neurons are excreting excess cholesterol, indicating cholesterol overload and early neurodegeneration risk; statins have been shown to reduce these levels.
Of all ApoB-lowering drug classes (statins, ezetimibe, PCSK9 inhibitors, bile acid sequestrants, CETP inhibitors), only statins can penetrate the blood-brain barrier and affect brain cholesterol synthesis.
Ezetimibe itself cannot cross the blood-brain barrier, but its metabolite ezetimibe glucuronide can penetrate in small amounts and has shown anti-inflammatory effects in the brain in animal studies.
Researcher Bill Harris has concluded that an omega-3 index of 8–9% in red blood cell membranes reflects adequate omega-3 content across the body's cell membranes, though no randomized trial has proven a specific brain benefit.
People with genetic CETP loss-of-function variants have lower rates of Alzheimer's disease and cognitive impairment, providing the biological rationale for testing CETP inhibitors as a neuroprotective strategy.
Once the brain reaches adult size around age 10, neurons stop making their own cholesterol to save ATP for firing action potentials. Astrocytes take over production, packaging cholesterol into ApoE-containing HDL-like particles that ferry it through the brain's interstitial fluid to waiting neurons.
A single amino acid difference between ApoE isoforms changes the protein's shape and function. Carrying two E4 copies raises Alzheimer's risk 8–12-fold over the E3/E3 baseline — a near full-log increase — because the ApoE4 protein is structurally inferior at delivering cholesterol to neurons.
APOE4 produces inferior ApoE proteins that bind poorly to neuronal receptors, starving neurons of cholesterol. Without proper membrane cholesterol, beta and gamma secretases cleave amyloid precursor protein into the toxic amyloid-beta-42 — the hallmark of Alzheimer's pathology.
All statins — hydrophilic or lipophilic — reach the brain in steady state and can reduce cholesterol synthesis there. Meta-analyses show statins are either neutral or beneficial for dementia risk, but some patients develop brain fog, which may reflect over-suppression. Plasma desmosterol can help calibrate the dose.
APOE4 brain HDL binds poorly to neuronal receptors, so instead of being internalized and releasing cholesterol into the cytosol, it only deposits cholesterol onto the cell membrane. The result is membrane overload and cytosolic deficiency simultaneously — a uniquely harmful double disruption.
When neurons accumulate too much cholesterol, they convert it to 24S-hydroxycholesterol — a water-soluble form that can escape through the blood-brain barrier into plasma. Elevated levels in blood signal neuronal cholesterol overload and early neurodegeneration risk; statins reduce these levels.
DHA and EPA reach brain cells via a phospholipid transfer protein shuttle that docks at a specific blood-brain barrier receptor. Both fatty acids matter — EPA is no longer considered secondary. An omega-3 index of 8–9% appears to be the saturation point for systemic cell membranes, though no RCT has proven a specific brain-health threshold.
Most people think LDL's job is delivering cholesterol to cells — it's not. Because every cell can synthesize its own cholesterol, LDL's primary function is returning cholesterol back to the liver. This is why lowering LDL is safe and why the HDL-only model of reverse cholesterol transport was always incomplete.
The brain holds roughly 20–25 grams of cholesterol — about 20 times more than the liver — and hoards it with a half-life of 5 years. The liver is a high-flux transit station; the brain is a locked vault.
Once ApoB-containing particles exceed a concentration threshold, they diffuse into the arterial wall, get oxidized, trigger macrophage infiltration, and form foam cells — the foundation of plaque. This is why ApoB particle number, not cholesterol content, is the true driver of cardiovascular risk.
Obicetrapib, a CETP inhibitor, raises ApoA-1 and generates tiny protein-rich HDL particles that can cross the blood-brain barrier. The BROADWAY trial showed movement in the right direction on phosphorylated tau, amyloid-40/42 ratios, and other Alzheimer's biomarkers — suggesting it may rescue dysfunctional APOE4 brain HDL.
Ezetimibe works in the gut and can't cross the blood-brain barrier — but its metabolite, ezetimibe glucuronide, can. Animal studies show it interferes with hexokinase and reduces brain protein glycosylation, producing anti-inflammatory effects. Neurologists already report anecdotal cognitive benefits in patients.
Astrocytes synthesize cholesterol via the desmosterol pathway, and plasma desmosterol correlates strongly with CSF desmosterol and brain cholesterol production. Studies show low plasma desmosterol is associated with higher rates of cognitive impairment — making it a clinically measurable proxy for brain cholesterol health.
The brain and body run completely separate cholesterol systems. ApoB-containing particles that carry most of your plasma cholesterol are far too large to cross the blood-brain barrier, meaning your LDL level has essentially zero bearing on brain cholesterol supply.
High LDL alone doesn't guarantee atherosclerosis — insulin resistance, chronic inflammation, blood pressure, and oxidative stress all determine how quickly damage accumulates. Some individuals appear genetically protected by unknown mechanisms, but betting on being one of them is playing Russian roulette.
Analysis
What they talk about
- Health & Fitness 64%
- Science 36%
Connections
Shows they appear on and people they share episodes with. Drag to explore.
